Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495706 | 0.84 | KCNH2 (0.47) | KCNH2SLC2A1CCR3TGFBR1 | |
| SCHEMBL5252383 | 0.83 | KCNH2 (0.60) | KCNH2SLC2A1 | |
| SCHEMBL5256973 | 0.83 | KCNH2 (0.60) | KCNH2SLC2A1 | |
| SCHEMBL5256971 | 0.83 | KCNH2 (0.60) | KCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL5253585 | 0.82 | KCNH2 (0.59) | KCNH2SLC2A1 | |
| SCHEMBL4477066 | 0.80 | SLC2A1 (0.46) | KCNH2SLC2A1MTNR1AMTNR1B | |
| Oxalic Acid SCHEMBL5418955 | 0.79 | SLC2A1 (0.64) | KCNH2SLC2A1 | |
| SCHEMBL1723516 | 0.75 | MTNR1A (0.45) | MTNR1AMTNR1BPRMT5WDR77MCHR1 | |
| SCHEMBL4489968 | 0.74 | MTNR1A (0.44) | KCNH2MTNR1AMTNR1BPRMT5WDR77 | |
| SCHEMBL5744804 | 0.74 | KCNH2 (0.50) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498326-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| EP-1583537-A3 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1583537-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004002490-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | TLR1, TLR2, TLR6 | KCNH2 1191/4885SLC2A1 3520/4885MTNR1A 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.